Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 11/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16303974 | 0.85 | NLRP3 (0.45) | NOTUMPIM1RXRAGRIN1GRIN2B | |
| SCHEMBL16297174 | 0.85 | GABRD (0.40) | NOTUMGABRDGABRA1GABRB2GABRA4 | |
| SCHEMBL16297261 | 0.83 | MEN1 (0.41) | MGLL | |
| SCHEMBL16297115 | 0.82 | PIM1 (0.53) | NOTUMPIM1RXRAGRIN1GRIN2B | |
| SCHEMBL16297298 | 0.81 | AKR1C3 (0.48) | PIM1RXRAGRIN1GRIN2BMGLL | |
| SCHEMBL16297285 | 0.81 | MEN1 (0.43) | NOTUMPIM1RXRAGRIN1GRIN2B | |
| SCHEMBL16296969 | 0.80 | KMT2A (0.41) | PIM1RXRAGRIN1GRIN2BCHRM4 | |
| SCHEMBL19118397 | 0.80 | NOTUM (0.36) | NOTUMPIM1RXRAGRIN1GRIN2B | |
| SCHEMBL16297289 | 0.80 | KDM4E (0.39) | NOTUMPIM1RXRAGRIN1GRIN2B | |
| SCHEMBL16296392 | 0.80 | NOTUM (0.46) | NOTUMPIM1RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | claimed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | claimed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014198592-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198592-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | TBXA2R, CYP11B2, NR1I2 | NOTUM 3450/4885PIM1 2738/4885RXRA 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.